CalciMedica Reveals Promising Data on CRAC Channel Inhibitor for Pulmonary Arterial Hypertension CalciMedica has announced exciting new preclinical findings regarding CM5480, a CRAC channel inhibitor, as a potential breakthrough treatment for pulmonary arterial hypertension.

CalciMedica Reveals Promising Data on CRAC Channel Inhibitor for Pulmonary Arterial Hypertension #USA #La_Jolla #CalciMedica #CRAC_channel #CM5480

CalciMedica to Present at H.C. Wainwright 27th Global Investment Conference 2025 CalciMedica, a biopharmaceutical company, will showcase its CRAC channel inhibition therapies at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025.

CalciMedica to Present at H.C. Wainwright 27th Global Investment Conference 2025 #CalciMedica #Auxora #CRAC_channel

CalciMedica CEO to Speak at H.C. Wainwright's Kidney Virtual Conference on Innovations in CRAC Channel Therapies CalciMedica will be presenting at the upcoming H.C. Wainwright Virtual Conference, focusing on novel therapies for inflammatory conditions.

CalciMedica CEO to Speak at H.C. Wainwright's Kidney Virtual Conference on Innovations in CRAC Channel Therapies #CalciMedica #Auxora #CRAC_channel